Digipath (OTCMKTS:DIGP) and Genpact (NYSE:G) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.
This table compares Digipath and Genpact’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Digipath -58.20% -126.57% -103.96% Genpact 9.40% 23.63% 9.22%
This is a summary of current recommendations and price targets for Digipath and Genpact, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Digipath 0 0 0 0 N/A Genpact 0 3 6 0 2.67
Genpact has a consensus target price of $34.83, suggesting a potential upside of 7.38%. Given Genpact’s higher possible upside, analysts plainly believe Genpact is more favorable than Digipath.
Valuation and Earnings
This table compares Digipath and Genpact’s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Digipath $2.84 million 3.71 -$1.65 million N/A N/A Genpact $3.00 billion 2.05 $282.02 million $1.60 20.28
Genpact has higher revenue and earnings than Digipath.
Volatility and Risk
Digipath has a beta of 4.99, indicating that its stock price is 399% more volatile than the S&P 500. Comparatively, Genpact has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
Insider & Institutional Ownership
0.5% of Digipath shares are held by institutional investors. Comparatively, 89.4% of Genpact shares are held by institutional investors. 1.9% of Genpact shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Genpact pays an annual